American Well Corporation (AMWL)
Healthcare
- Fundamental
- 2
- Sentiment
- 2
- Technical
- 2
Do Nothing: fundamentalScore 2 and qualitativeScore 2 are both below the required floor of 3 (no SHADOW branch — the shadow sum-gate flag is false), and the 20-day average dollar volume of $1.83M is below the $5M liquidity floor; no entry was sized, and on the chart neither a pullback limit (countertrend: price 12.42 below SMA50 12.99 with MACD -0.18) nor a breakout stop (above 12.61/13.81 resistance, with negative momentum on a thin tape) qualifies.
Company overview
American Well Corporation provides a digital platform for hybrid healthcare delivery in the U.S. and internationally. Its offerings include cloud-based platforms, device-enabled access points, and specialty care programs. The company serves healthcare providers, payers, government, and higher education sectors.
Fundamental
weakAmerican Well is a cash-rich, debt-free telehealth platform with declining revenue and persistent losses, indicating a speculative recovery profile.
Weak but stabilizing: a debt-free telehealth platform with $180.8M of cash and a collapse in cash burn, offset by a ~20% revenue decline, persistent GAAP losses, falling backlog and both DCF models below the current share price. Speculative recovery profile, not investment-grade on fundamentals.
Sentiment
weakSentiment is neutral with no upcoming catalysts and a mixed reception to recent earnings.
Dominant driver is the Q3 2026 earnings print (announced, 2026-11-03): a revenue beat with raised FY2026 guidance and a first positive Q4 adjusted EBITDA target, offset by an EPS loss of $0.67 versus consensus, ~13% lower revenue and a neutral post-print analyst stance after a ~8% share pullback — mixed on reception and already largely absorbed, with only a routine $13 price-target raise (about 2% implied upside) alongside it. The sentiment delta is determinate but flat (baseline polarity_score ≈ +0.02 versus scoring ≈ +0.01, both windows diluted by off-topic name-collision items) and retail is indeterminate after repeated Reddit access blocks; the Red-Flag Screen is clean, so no cap applies and the weak, absent-to-weak setup reflects the absence of any forward-dated catalyst across the next 30 trading days.
Technical
weakThe technical setup shows a short-term downtrend within a long-term uptrend, with no confirmed trend reversal.
AMWL scores 2/5 on the chart. The last daily close (12.42 on 2026-11-11, matching the live quote at 12.42) sits below SMA20 12.94, SMA50 12.99, EMA9 12.49, EMA21 12.75 and WMA21 12.81, but above SMA200 9.23, DEMA14 12.36, TEMA14 12.13, WMA9 12.28 and the session VWAP 12.28 — a short-term downtrend nested inside a long-term uptrend, still repairing the 2026-10-30 -14.1% drop that carried the stock from a 15.16 high to an 11.26 low on 2026-11-10. Momentum is negative and deteriorating: MACD line -0.18 under signal -0.05 with histogram -0.14, negative for seven straight sessions since 2026-11-04 and down from +0.21 on 2026-10-29; RSI14 46.94 is neutral, Williams %R -70.26 weak, and ADX14 11.00 says there is no directional trend at all. ATR14 is 0.94, or 7.62% of the 12.33 snapshot price — a high-volatility name — while 20-day dollar volume is only about $1.83M/day. The bounce off 11.26 is constructive but unconfirmed: this is a bounce-only, base-building tape rather than one of the five tradable bullish setups, and the fundamental floor (2), qualitative floor (2) and the $5M liquidity floor each independently suppress any entry.
You’re looking at 2026-11-11 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

